Obesity currently affects 78.6 million people (33%) in the United States and is expected to increase to over 50% of the population by 2030. This epidemic is fueled by the growing rate of obesity in adolescents. The new science of obesity indicates that there is a tipping point at which genetic resetting occurs and it is reached when adipose tissue dysfunction occurs. It is becoming clear that obesity is less an ongoing personal choice than a fact of biology. With this review, we aim to describe the epidemiology of obesity and the associated comorbidities.
Get full access to this article
View all access options for this article.
References
1.
FinkelsteinEA, KhavjouOA, ThompsonH, TrogdonJG, PanL, SherryB, et al.Obesity and severe obesity forecasts through 2030. Am J Prev Med, 2012; 42:563–570.
2.
OgdenCL, CarrollMD, KitBK, FlegalKM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA, 2014; 311:806–814.
3.
BergmanRN.A better index of body adiposity. Obesity (Silver Spring), 2012; 20:1135.
4.
HsuWC, AranetaMR, KanayaAM, ChiangJL, FujimotoW. BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening. Diabetes Care, 2015; 38:150–158.
5.
MustA, AndersonSE. Body mass index in children and adolescents: Considerations for population-based applications. Int J Obes (Lond), 2006; 30:590–594.
6.
AndreyevaT, SturmR, RingelJS. Moderate and severe obesity have large differences in health care costs. Obes Res, 2004; 12:1936–1943.
7.
CaliAM, CaprioS. Obesity in children and adolescents. J Clin Endocrinol Metab, 2008; 93,(11 Suppl 1):S31–S36.
8.
CunninghamSA, KramerMR, NarayanKM. Incidence of childhood obesity in the United States. N Engl J Med, 2014; 370:1660–1661.
9.
KochanekKD, MurphySL, XuJQ, AriasE. Mortality in the United States, 2016. Hyattsville, MD: National Center for Health Statistics; 2017. NCHS Data Brief No. 293.
10.
OlshanskySJ, PassaroDJ, HershowRC, LaydenJ, CarnesBA, BrodyJ, et al.A potential decline in life expectancy in the United States in the 21st century. N Engl J Med, 2005; 352:1138–1145.
11.
DeanH, FlettB. Natural history of type 2 diabetes diagnosed in childhood: Long term follow up in young adult years. Diabetes, 2002; 51:A24.
12.
VincentGK, VelkoffVA. The next four decades, the older population in the United States: 2010 to 2050. Washington, D.C.: U.S. Census Bureau; 2010. Current Population Reports, P25-1138.
13.
JamesWP.The fundamental drivers of the obesity epidemic. Obes Rev, 2008; 9(Suppl 1):6–13.
14.
NgM, FlemingT, RobinsonM, ThomsonB, GraetzN, MargonoC, et al.Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2014; 384:766–781.
15.
GeissLS, WangJ, ChengYJ, ThompsonTJ, BarkerL, LiY, et al.Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980–2012. JAMA, 2014; 312:1218–1226.
16.
MenkeA, CasagrandeS, GeissL, CowieCC. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA, 2015; 314:1021–1029.
17.
KirbyJB, LiangL, ChenHJ, WangY. Race, place, and obesity: The complex relationships among community racial/ethnic composition, individual race/ethnicity, and obesity in the United States. Am J Public Health, 2012; 102:1572–1578.
18.
BleichSN, ThorpeRJJr., Sharif-HarrisH, FesahazionR, LaveistTA.Social context explains race disparities in obesity among women. J Epidemiol Community Health, 2010; 64:465–469.
19.
ThorpeRJJr., KelleyE, BowieJV, GriffithDM, BruceM, LaVeistT.Explaining racial disparities in obesity among men: Does place matter?. Am J Mens Health, 2015; 9:464–472.
20.
PedersenDJ, GuilhermeA, DanaiLV, HeydaL, MatevossianA, CohenJ, et al.A major role of insulin in promoting obesity-associated adipose tissue inflammation. Mol Metab, 2015; 4:507–518.
21.
FordES, WilliamsonDF, LiuS. Weight change and diabetes incidence: Findings from a national cohort of US adults. Am J Epidemiol, 1997; 146:214–222.
22.
MeigsJB, RutterMK, SullivanLM, FoxCS, D'AgostinoRBSr., WilsonPW. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care, 2007; 30:1219–1225.
23.
AliMK, BullardKM, SaaddineJB, CowieCC, ImperatoreG, GreggEW. Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med, 2013; 368:1613–1624.
24.
Pi-SunyerFX.Weight loss in type 2 diabetic patients. Diabetes Care, 2005; 28:1526–1527.
25.
ZhangXQ, XuCF, YuCH, ChenWX, LiYM. Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol, 2014; 20:1768–1776.
26.
SavageDB, PetersenKF, ShulmanGI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev, 2007; 87:507–520.
27.
XuW, ShubinaM, GoldbergSI, TurchinA. Body mass index and all-cause mortality in patients with hypertension. Obesity (Silver Spring), 2015; 23:1712–1720.
28.
HsuCY, McCullochCE, IribarrenC, DarbinianJ, GoAS. Body mass index and risk for end-stage renal disease. Ann Intern Med, 2006; 144:21–28.
29.
BueterM, AhmedA, AshrafianH, le RouxCW. Bariatric surgery and hypertension. Surg Obes Relat Dis, 2009; 5:615–620.
30.
Luna-LunaM, Medina-UrrutiaA, Vargas-AlarconG, Coss-RovirosaF, Vargas-BarronJ, Perez-MendezO. Adipose tissue in metabolic syndrome: Onset and progression of atherosclerosis. Arch Med Res, 2015; 46:392–407.
31.
ChiaraTD, ArganoC, ScaglioneA, CorraoS, PintoA, ScaglioneR. Circulating adiponectin: A cardiometabolic marker associated with global cardiovascular risk. Acta Cardiol, 2015; 70:33–40.
32.
KhavandiK, KhavandiA, AsgharO, GreensteinA, WithersS, HeagertyAM, et al.Diabetic cardiomyopathy—A distinct disease?. Best Pract Res Clin Endocrinol Metab, 2009; 23:347–360.
33.
WaddinghamMT, EdgleyAJ, TsuchimochiH, KellyDJ, ShiraiM, PearsonJT. Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy. World J Diabetes, 2015; 6:943–960.
FriedenbergFK, XanthopoulosM, FosterGD, RichterJE. The association between gastroesophageal reflux disease and obesity. Am J Gastroenterol, 2008; 103:2111–2122.
36.
LockeGR3rd, TalleyNJ, FettSL, ZinsmeisterAR, MeltonLJ3rd.Risk factors associated with symptoms of gastroesophageal reflux. Am J Med, 1999; 106:642–649.
NadaletoBF, HerbellaFA, PattiMG. Gastroesophageal reflux disease in the obese: Pathophysiology and treatment. Surgery, 2016; 159:475–486.
39.
WuJC, MuiLM, CheungCM, ChanY, SungJJ. Obesity is associated with increased transient lower esophageal sphincter relaxation. Gastroenterology, 2007; 132:883–889.
40.
TutuianR.Obesity and GERD: Pathophysiology and effect of bariatric surgery. Curr Gastroenterol Rep, 2011; 13:205–212.
41.
SalomeCM, KingGG, BerendN. Physiology of obesity and effects on lung function. J Appl Physiol (1985), 2010; 108:206–211.
42.
PapoutsakisC, PriftisKN, DrakouliM, PriftiS, KonstantakiE, ChondronikolaM, et al.Childhood overweight/obesity and asthma: Is there a link? A systematic review of recent epidemiologic evidence. J Acad Nutr Diet, 2013; 113:77–105.
43.
SoodA, ShoreSA. Adiponectin, leptin, and resistin in asthma: Basic mechanisms through population studies. J Allergy (Cairo), 2013; 2013:785835.
44.
LeinumCJ, DoppJM, MorganBJ. Sleep-disordered breathing and obesity: Pathophysiology, complications, and treatment. Nutr Clin Pract, 2009; 24:675–687.
